Australian Clinical Labs (ACL) AGM 2025 summary

Opening remarks and agenda

• Meeting opened by new Chair Stephen Roach, who acknowledged the traditional custodians, including the Darug people of the Eora Nation, and confirmed a quorum.

• Board members, key executives, and the auditor were introduced, with the auditor available for questions on financial statements.

• Voting and question procedures for the virtual AGM were explained, including contingency plans for technical issues.

• The agenda included the Chair's address, CEO's address, financial and operational overview, formal business, and Q&A.

Financial performance review

• Revenue for FY2025 reached $741.3 million, a 6.4% year-on-year increase, outpacing market growth despite challenging conditions.

• Underlying EBIT rose 8.7% to $68 million, with a margin of 9.2% and a strong second-half EBIT margin of 10.9%.

• Free cash flow increased 30.2% to $70.8 million, driven by operating leverage and positive working capital management.

• Net debt to EBITDA improved to 0.3x after $13 million in debt repayment; net debt was reduced by $8.4 million.

• $44 million was returned to shareholders via $25 million in dividends and $19 million in share buybacks, totaling about 9% of market capitalization.

Board and executive committee updates

• Stephen Roach succeeded Michael Ulsher as Chair earlier in the year.

• Dr. Leanne Rowe resigned from the Board for personal reasons; her re-election resolution was withdrawn.

• New directors Sarah Butler and Grant Jeffery stood for formal re-election after joining as casual vacancies.